Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did

Executive Summary

Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.

Advertisement

Related Content

Sanofi Looks To Lead In Consumer Following Trade With Boehringer Ingelheim
Sanofi Looks To Lead In Consumer Following Trade With Boehringer Ingelheim
AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture
Deal Watch: NASH Space Heats Up With Tobira/Regado Reverse-Merger
Pfizer’s Latest Palbociclib Data Could Mean Slimmer Lead Over CDK4/6 Rivals
Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback
Novartis Ups The Ante In Immunotherapy With CoStim Buy
Novartis Counting On Depth Of Insight To Continue Success In Oncology
In Oncology, Drug Makers Jostle For Second Place
GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056073

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel